Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 2, 2015, Pages 165-171

  Rhodes, Nathaniel J ^a,b   Liu, Jiajun ^a   McLaughlin, Milena M ^a,b   Qi, Chao ^b   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Bloodstream infection; Cefepime; Gram negative bacteria; Minimum inhibitory concentration; Mortality

Indexed keywords

CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER; ADULT; ARTICLE; BLOODSTREAM INFECTION; COHORT ANALYSIS; DEMOGRAPHY; ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS; RETROSPECTIVE STUDY; SCORING SYSTEM; SCREENING; SURVIVAL; AGED; BACTEREMIA; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CEPHALOSPORINS; COHORT STUDIES; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84929047526     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.03.005     Document Type: Article

References (22)

1. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P., Acute Dialysis Quality Initiative, w Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
2. Bhat S.V., Peleg A.Y., Lodise T.P., Shutt K.A., Capitano B., Potoski B.A., et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007, 51:4390-4395.
3. Chopra T., Marchaim D., Veltman J., Johnson P., Zhao J.J., Tansek R., et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012, 56:3936-3942.
4. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. M100-S20 2010, [Wayne, PA].
5. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. M100-S23 2013, [Wayne, PA].
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. M100-S24 2014, [Wayne, PA].
7. Esterly J.S., Wagner J., McLaughlin M.M., Postelnick M.J., Qi C., Scheetz M.H. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 2012, 56:4885-4890.
8. Hamilton K.W., Bilker W.B., Lautenbach E. Controlling for severity of illness in assessment of the association between antimicrobial-resistant infection and mortality: impact of calculation of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at different time points. Infect Control Hosp Epidemiol 2007, 28:832-836.
9. Hosmer D.W., Lemeshow S. Applied logistic regression 2000, Wiley, New York. 2nd ed.
10. Hospira MAXIPIME (cefepime hydrochloride) IV package insert 2013, Hospira, Inc., Lake Forest, IL.
11. Kuti J.L., Dandekar P.K., Nightingale C.H., Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003, 43:1116-1123.
12. Kuti J.L., Nightingale C.H., Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 2004, 48:2464-2470.
13. Lee S.Y., Kuti J.L., Nicolau D.P. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect 2007, 54:463-468.
14. Lee N.Y., Lee C.C., Huang W.H., Tsui K.C., Hsueh P.R., Ko W.C. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013, 56:488-495.
15. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
16. Nicasio A.M., Ariano R.E., Zelenitsky S.A., Kim A., Crandon J.L., Kuti J.L., et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53:1476-1481.
17. Song W., Moland E.S., Hanson N.D., Lewis J.S., Jorgensen J.H., Thomson K.S. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005, 43:4891-4894.
18. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2014 Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0 2014, vol. 2014.
19. Thom K.A., Shardell M.D., Osih R.B., Schweizer M.L., Furuno J.P., Perencevich E.N., et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008, 29:1048-1053.
20. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994.
21. Ury H.K. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975, 31:643-649.
22. Wi Y.M., Kang C.I., Cheong H.S., Chung D.R., Jung C.W., Ko K.S., et al. Failure of cefepime therapy in neutropenic patients with extended-spectrum beta-lactamase-producing Gram-negative bacteraemia. Int J Antimicrob Agents 2009, 33:384-386.